<DOC>
	<DOCNO>NCT01433354</DOCNO>
	<brief_summary>The purpose study generate long-term safety , tolerability efficacy data AFQ056 eligible adolescent patient FXS participate CAFQ056B2214 study , PK study CAFQ056B2131 , another study AFQ056 include FXS patient 18 year age provide patient least 12 year age time entry current study .</brief_summary>
	<brief_title>Long-term , Safety Tolerability Study AFQ056 Adolescent Patients With Fragile X Syndrome ( Open-label )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<criteria>Group 1 patient : Must complete study CAFQ056B2214 another study AFQ056 include FXS patient 18 year age within one week enrollment openlabel study . Has caregiver caregiver spend , average , least 6 hour per day patient , willing capable supervising treatment , provide input efficacy safety assessment , accompany patient study visit . Group 2 patient : Must meet one follow condition : Completed Study CAFQ056B2131 Completed Study CAFQ056B2214 another study AFQ056 include FXS patient 18 year age enrollment current study delay week . Discontinued prematurely Study CAFQ056B2214 another study AFQ056 include FXS patient 18 year age due intolerability dosage patient 's assigned treatment group . Has caregiver caregiver spend , average , least 6 hour per day patient , willing capable supervising treatment , provide input efficacy safety assessment , accompany patient study visit . Discontinuation Study CAFQ056B2214 CAFQ056B2131 another study AFQ056 include FXS patient 18 year age due safety reason Female patient sexually active time study Any advance , severe unstable disease History and/or presence schizophrenia , bipolar disease , psychosis , confusional state and/or repeat hallucination per DSMIV criterion History suicidal behavior consider high suicidal risk History severe selfinjurious behavior History uncontrolled seizure disorder resistant therapy within past 2 year ( Patients clinically stable anticonvulsant therapy past 2 year exclude ) History clinically significant allergy require hospitalization noninhaled corticosteroid therapy ( asthma , anaphylaxis , etc . ) History malignancy organ system ( localize basal cell carcinoma skin ) , treat untreated , within past 5 year , regardless whether evidence local recurrence metastasis Patients use ( use within 6 week baseline ) digoxin warfarin Using ( use within 6 week baseline ) concomitant medication potent inhibitor inducer CYP3A4 Using glutamatergic agent ( riluzole , memantine , etc . ) lithium within 6 week baseline Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Fragile X Syndrome</keyword>
	<keyword>Martin-Bell Syndrome</keyword>
	<keyword>Genetic Diseases</keyword>
	<keyword>X-Linked</keyword>
	<keyword>Escalante 's syndrome</keyword>
</DOC>